Effects of CCK-8 on the reinstatement of morphine-induced CPP and expression of behavioral sensitization in rats

Neuroscience

Volumn 238, Issue , 2013, Pages 230-241

  Wen, D ^a   Zang, G ^a   Sun, D ^a   Yang, S ^a   Yu, F ^a   Li, S ^a   Ma, C ^a   Cong, B ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Behavioral sensitization; Cholecystokinin octapeptide; Conditioned place preference; Drug relapse; Morphine; Reinstatement

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; MORPHINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SEEKING BEHAVIOR; FOOTSHOCK; LOCOMOTION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT;

ANIMALS; ASSOCIATION LEARNING; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-SEEKING BEHAVIOR; EXTINCTION, PSYCHOLOGICAL; MALE; MORPHINE; MOTOR ACTIVITY; NARCOTICS; RATS; RATS, WISTAR; SINCALIDE;

EID: 84875843034     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.02.057     Document Type: Article

References (77)

1. Adinoff B. Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004, 12:305-320.
2. Anokhina I.P., Proskuriakova T.V. Involvement of the neuropeptide cholecystokinin in the mechanisms of regulation of emotions and craving. Vestn Ross Akad Med Nauk 2002, 6:36-40.
3. Baber N.S., Dourish C.T., Hill D.R. The role of CCK caerulein, and CCK antagonists in nociception. Pain 1989, 39:307-328.
4. Balschun D., Reymann K.G. Cholecystokinin (CCK-8S) prolongs 'unsaturated' theta-pulse induced long-term potentiation in rat hippocampal CA1 in vitro. Neuropeptides 1994, 26:421-427.
5. Beresford I.J., Hall M.D., Clark C.R., Hill R.G., Hughes J. Cholecystokinin modulation of [3H]noradrenaline release from superfused hypothalamic slices. Neurosci Lett 1988, 88:227-232.
6. Biro E., Penke B., Telegdy G. Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats. Neuropeptides 1997, 31:281-285.
7. Campiani G., Butini S., Trotta F., Fattorusso C., Catalanotti B., Aiello F., Gemma S., Nacci V., Novellino E., Stark J.A., Cagnotto A., Fumagalli E., Carnovali F., Cervo L., Mennini T. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 2003, 46:3822-3839.
8. Cesselin F. Opioid and anti-opioid peptides. Fundam Clin Pharmacol 1995, 9:409-433.
9. Chen J.C., Chen P.C., Chiang Y.C. Molecular mechanisms of psychostimulant addiction. Chang Gung Med J 2009, 32:148-154.
10. Colasanti A., Rabiner E.A., Lingford-Hughes A., Nutt D.J. Opioids and anxiety. J Psychopharmacol 2011, 25:1415-1433.
11. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides 1994, 15:731-755.
12. Dauge V., Lena I. CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 1998, 22:815-825.
13. Di Ciano P., Blaha C.D., Phillips A.G. Changes in dopamine efflux associated with extinction, CS-induced and d-amphetamine-induced reinstatement of drug-seeking behavior by rats. Behav Brain Res 2001, 120:147-158.
14. Doi T., Jurna I. Analgesic effect of intrathecal morphine demonstrated in ascending nociceptive activity in the rat spinal cord an in effectiveness of caerulein and cholecystokinin octapeptide. Brain Res 1982, 234:399-407.
15. Dolberg O.T., Iancu I., Sasson Y., Zohar J. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 1996, 19:129-147.
16. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., Iversen S.D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990, 176:35-44.
17. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219:310-312.
18. Fenu S., Spina L., Rivas E., Longoni R., Di Chiara G. Morphine-conditioned single-trial place preference: role of nucleus accumbens shell dopamine receptors in acquisition, but not expression. Psychopharmacology (Berl) 2006, 187:143-153.
19. Frenois F., Le Moine C., Cador M. The motivational component of withdrawal in opiate addiction: role of associative learning and aversive memory in opiate addiction from a behavioral, anatomical and functional perspective. Rev Neurosci 2005, 16:255-276.
20. Gal K., Gyertyan I. Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats. Brain Res Bull 2003, 61:595-601.
21. Gospic K., Gunnarsson T., Fransson P., Ingvar M., Lindefors N., Petrovic P. Emotional perception modulated by an opioid and a cholecystokinin agonist. Psychopharmacology (Berl) 2008, 197:295-307.
22. Gulpinar M.A., Yegen B.C. The physiology of learning and memory: role of peptides and stress. Curr Protein Pept Sci 2004, 5:457-473.
23. Hadjiivanova C., Belcheva S., Belcheva I. Cholecystokinin and learning and memory processes. Acta Physiol Pharmacol Bulg 2003, 27:83-88.
24. Hebb A.L., Zacharko R.M., Dominguez H., Laforest S., Gauthier M., Levac C., Drolet G. Changes in brain cholecystokinin and anxiety-like behavior following exposure of mice to predator odor. Neuroscience 2003, 116:539-551.
25. Hebb A.L., Poulin J.F., Roach S.P., Zacharko R.M., Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:1225-1238.
26. Heinricher M.M., Neubert M.J. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004, 92:1982-1989.
27. Hirosue Y., Inui A., Miura M., Nakajima M., Okita M., Himori N., Baba S., Kasuga M. Effects of CCK antagonists on CCK-induced suppression of locomotor activity in mice. Peptides 1992, 13:155-157.
28. Horio M., Kohno M., Fujita Y., Ishima T., Inoue R., Mori H., Hashimoto K. Role of serine racemase in behavioral sensitization in mice after repeated administration of methamphetamine. PLoS One 2012, 7:e35494.
29. Itoh S., Katsuura G., Maeda Y. Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol 1982, 80:421-425.
30. Itoh S., Katsuura G., Takashima A. Interactions of cholecystokinin, beta-endorphin, and their antagonists on passive avoidance behavior in rats. Can J Physiol Pharmacol 1987, 65:2260-2264.
31. Jutkiewicz E.M., Roques B.P. Endogenous opioids as physiological antidepressants: complementary role of delta receptors and dopamine. Neuropsychopharmacology 2012, 37:303-304.
32. Katz J.L., Higgins S.T. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl) 2003, 168:21-30.
33. Koks S., Abramov U., Veraksits A., Bourin M., Matsui T., Vasar E. CCK2 receptor-deficient mice have increased sensitivity of dopamine D2 receptors. Neuropeptides 2003, 37:25-29.
34. Koob G.F. Hedonic homeostatic dysregulation as a driver of drug-seeking behavior. Drug Discov Today Dis Models 2008, 5:207-215.
35. Koob G.F., Rocio M., Carrera A., Gold L.H., Heyser C.J., Maldonado-Irizarry C., Markou A., Parsons L.H., Roberts A.J., Schulteis G., Stinus L., Walker J.R., Weissenborn R., Weiss F. Substance dependence as a compulsive behavior. J Psychopharmacol 1998, 12:39-48.
36. Ladurelle N., Keller G., Blommaert A., Roques B.P., Dauge V. The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur J Neurosci 1997, 9:1804-1814.
37. Lankisch T.O., Tsunoda Y., Lu Y., Owyang C. Characterization of CCK(A) receptor affinity states and Ca(2+) signal transduction in vagal nodose ganglia. Am J Physiol Gastrointest Liver Physiol 2002, 282:G1002-1008.
38. Lemaire M., Piot O., Roques B.P., Bohme G.A., Blanchard J.C. Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport 1992, 3:929-932.
39. Lu L., Huang M., Liu Z., Ma L. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuroreport 2000, 11:829-832.
40. Lu L., Huang M., Ma L., Li J. Different role of cholecystokinin (CCK)-A and CCK-B receptors in relapse to morphine dependence in rats. Behav Brain Res 2001, 120:105-110.
41. Lu L., Zhang B., Liu Z.Y., Zhang Z.Y. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats. Brain Res 2002, 954:132-140.
42. Ma K.T., Si J.Q., Zhang Z.Q., Zhao L., Fan P., Jin J.L., Li X.Z., Zhu L. Modulatory effect of CCK-8S on GABA-induced depolarization from rat dorsal root ganglion. Brain Res 2006, 1121:66-75.
43. Mannisto P.T., Lang A., Harro J., Peuranen E., Bradwejn J., Vasar E. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol 1994, 349:478-484.
44. Mitchell J.M., Bergren L.J., Chen K.S., Fields H.L. Cholecystokinin is necessary for the expression of morphine conditioned place preference. Pharmacol Biochem Behav 2006, 85:787-795.
45. Moran T.H., Robinson P.H., Goldrich M.S., McHugh P.R. Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 1986, 362:175-179.
46. Mutschler N.H., Bergman J. Effects of chronic administration of the D1 receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl) 2002, 160:362-370.
47. Neisewander J.L., O'Dell L.E., Tran-Nguyen L.T., Castaneda E., Fuchs R.A. Dopamine overflow in the nucleus accumbens during extinction and reinstatement of cocaine self-administration behavior. Neuropsychopharmacology 1996, 15:506-514.
48. Nomoto S., Miyake M., Ohta M., Funakoshi A., Miyasaka K. Impaired learning and memory in OLETF rats without cholecystokinin (CCK)-A receptor. Physiol Behav 1999, 66:869-872.
49. O'Brien C.P. A range of research-based pharmacotherapies for addiction. Science 1997, 278:66-70.
50. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology (Berl) 1991, 103:480-492.
51. Perez de la Mora M., Hernandez-Gomez A.M., Arizmendi-Garcia Y., Jacobsen K.X., Lara-Garcia D., Flores-Gracia C., Crespo-Ramirez M., Gallegos-Cari A., Nuche-Bricaire A., Fuxe K. Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [3H]GABA release. Eur J Neurosci 2007, 26:3614-3630.
52. Phillips G.D., Le Noury J., Wolterink G., Donselaar-Wolterink I., Robbins T.W., Everitt B.J. Cholecystokinin-dopamine interactions within the nucleus accumbens in the control over behaviour by conditioned reinforcement. Behav Brain Res 1993, 55:223-231.
53. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G., Schwartz J.C., Everitt B.J., Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999, 400:371-375.
54. Pommier B., Beslot F., Simon A., Pophillat M., Matsui T., Dauge V., Roques B.P., Noble F. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. J Neurosci 2002, 22:2005-2011.
55. Powell J., Dawe S., Richards D., Gossop M., Marks I., Strang J., Gray J. Can opiate addicts tell us about their relapse risk? Subjective predictors of clinical prognosis. Addict Behav 1993, 18:473-490.
56. Reum T., Schafer U., Marsden C.A., Fink H., Morgenstern R. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry. Neuropeptides 1997, 31:82-88.
57. Reum T., Fink H., Marsden C.A., Morgenstern R. Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry. Neuropeptides 1998, 32:161-166.
58. Rezayat M., Nikfar S., Zarrindast M.R. CCK receptor activation may prevent tolerance to morphine in mice. Eur J Pharmacol 1994, 254:21-26.
59. Rezayat M., Azizi N., Zarrindast M.R. On the mechanism(s) of cholecystokinin (CCK): receptor stimulation attenuates morphine dependence in mice. Pharmacol Toxicol 1997, 81:124-129.
60. Rezayof A., Nazari-Serenjeh F., Zarrindast M.R., Sepehri H., Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur J Pharmacol 2007, 562:92-102.
61. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18:247-291.
62. Schank J.R., Pickens C.L., Rowe K.E., Cheng K., Thorsell A., Rice K.C., Shaham Y., Heilig M. Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) 2012, 218:111-119.
63. Self D.W. Neural substrates of drug craving and relapse in drug addiction. Ann Med 1998, 30:379-389.
64. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003, 168:3-20.
65. Smyth B.P., Barry J., Keenan E., Ducray K. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J 2010, 103:176-179.
66. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999, 22:521-527.
67. Stengel A., Goebel M., Million M., Stenzel-Poore M.P., Kobelt P., Monnikes H., Tache Y., Wang L. Corticotropin-releasing factor-overexpressing mice exhibit reduced neuronal activation in the arcuate nucleus and food intake in response to fasting. Endocrinology 2009, 150:153-160.
68. Taghzouti K., Lena I., Dellu F., Roques B.P., Dauge V., Simon H. Cognitive enhancing effects in young and old rats of pBC264, a selective CCK(B) receptor agonist. Psychopharmacology (Berl) 1999, 143:141-149.
69. Tzschentke T.M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007, 12:227-462.
70. Van Kampen J., Frydryszak H., Stoessl A.J. Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. Eur J Pharmacol 1996, 298:7-15.
71. Vanderschuren L.J., Pierce R.C. Sensitization processes in drug addiction. Curr Top Behav Neurosci 2010, 3:179-195.
72. Watkins L.R., Kinscheck I.B., Kaufman E.F., Miller J., Frenk H., Mayer D.J. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res 1985, 327:181-190.
73. Wei X., Zhang Z., Zhao L., Si J. CCK-8S inhibited the NMDA-activated current of cultured hippocampal neuron under normal and ethanol exposure conditions. Neurosci Lett 2009, 449:34-37.
74. Wen D., Ma C.L., Cong B., Yu H.L., Yu F., Ni Z.Y., Li S.J. Interaction of CCK-8 and endogenous opioid system in the opioid dependence. Chin Pharmacol Bull 2010, 26:421-426.
75. Wen D., Cong B., Ma C., Yang S., Yu H., Ni Z., Li S. The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP. Neurosci Lett 2012, 510:24-28.
76. Wen D., Ma C.L., Zhang Y.J., Meng Y.X., Ni Z.Y., Li S.J., Cong B. Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence. BMC Neurosci 2012, 13:63.
77. Yang S., Ling Y., Ling Y., Duan G., Wang J. Effect of cholecystokinin-octapeptide on focal cerebral ischemia/reperfusion injury in rats. Chin J Pathophysiol 2003, 19:472-476.